New targeted lung cancer therapies against RET, KRAS and c-MET are all outperforming standard of care in the clinic, including checkpoint inhibitors. But whether these therapies see uptake will likely depend more on whether next-generation...
DISEASE CATEGORY: Cancer INDICATION: Non-small cell lung cancer (NSCLC) A dual ROS1 and pan-NTRK inhibitor from Daiichi Sankyo Co. Ltd. could treat Xalkori crizotinib-resistant NSCLC, which has been linked to ROS1 mutations. In vitro high...
...Therapeutics Co. Ltd.
Johnson & Johnson
Memorial Sloan Kettering Cancer Center
Miltenyi Biotec GmbH
Suzhou Alphamab Co. Ltd.
c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR)